PROMISE‑MINO: A Prospective, Open‑Label, Multicenter, Single‑Arm, Phase IV Study of the Safety, Local Tolerability, and Efficacy of Topical Minocycline Hydrochloride 4% Gel in Indian Patients With Moderate‑to‑Severe Acne Vulgaris
Topical minocycline 4% gel showed an acceptable safety and tolerability profile with no new safety signals. Additionally, there was a clinically significant reduction in both inflammatory and non-inflammatory lesion counts, as well as a good IGA treatment success rate. Thus, it can be considered as an alternative for managing moderate-to-severe acne vulgaris.
Authors
- Ashwin Balasubramanian (ORCID: https://orcid.org/0000-0002-8645-6804)
- Mamta Bhura
- Prerna R. Suryatale
- Dhiraj Dhoot
- Abhishek De
- Sumit Bhushan
- Richa Gupta
- Hanmant Barkate
- Vishalakshi Viswanath
- H Banguru
- Vijay Sonkar
- Rujuta Gadkari
- Saiprasad Patil
- Swetalina Pradhan
Institutions
- Gandhi Medical College & Hospital (IN)
- Indira Gandhi Institute of Medical Sciences (IN)
- Sarojini Naidu Medical College (IN)
- Ahmedabad Civil Hospital (IN)
- SKiN Health (CA)
- Rajendra Hospital (IN)
- Glenmark Pharmaceuticals (India) (IN)
- Jefferson Hospital (US)
- Gandhi Medical College (IN)
- All India Institute of Medical Sciences (IN)
- Indus University (IN)
- Indian Institute of Technology Kanpur (IN)
Publication Details
- Journal
- Cureus
- Published
- 2026-01-15
- DOI
- https://doi.org/10.7759/cureus.101599
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Glenmark Pharmaceuticals